EP3150608B1 - 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment - Google Patents

2' -fluoro substituted carba-nucleoside analogs for antiviral treatment Download PDF

Info

Publication number
EP3150608B1
EP3150608B1 EP16196457.2A EP16196457A EP3150608B1 EP 3150608 B1 EP3150608 B1 EP 3150608B1 EP 16196457 A EP16196457 A EP 16196457A EP 3150608 B1 EP3150608 B1 EP 3150608B1
Authority
EP
European Patent Office
Prior art keywords
another aspect
alkyl
compound
methyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16196457.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3150608A1 (en
Inventor
Aesop Cho
Choung U. Kim
Samuel E. Metobo
Adrian S. Ray
Jie Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of EP3150608A1 publication Critical patent/EP3150608A1/en
Application granted granted Critical
Publication of EP3150608B1 publication Critical patent/EP3150608B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C7/00—Multicolour photographic processes or agents therefor; Regeneration of such processing agents; Photosensitive materials for multicolour processes
    • G03C7/30—Colour processes using colour-coupling substances; Materials therefor; Preparing or processing such materials
    • G03C7/32—Colour coupling substances
    • G03C7/36—Couplers containing compounds with active methylene groups
    • G03C7/38—Couplers containing compounds with active methylene groups in rings
    • G03C7/381—Heterocyclic compounds
    • G03C7/382—Heterocyclic compounds with two heterocyclic rings
    • G03C7/3825—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms
    • G03C7/3835—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms four nitrogen atoms

Definitions

  • the invention relates generally to compounds with antiviral activity, more particularly nucleosides active against Flaviviridae infections and most particularly to inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
  • Viruses comprising the Flaviviridae family comprise at least three distinquishable genera including pestiviruses, flaviviruses, and hepaciviruses ( Calisher, et al., J. Gen. Virol., 1993, 70, 37-43 ). While pestiviruses cause many economically important animal diseases such as bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, hog cholera) and border disease of sheep (BDV), their importance in human disease is less well characterized ( Moennig, V., et al., Adv. Vir. Res. 1992, 48, 53-98 ).
  • BVDV bovine viral diarrhea virus
  • CSFV classical swine fever virus
  • BDV border disease of sheep
  • Flaviviruses are responsible for important human diseases such as dengue fever and yellow fever while hepaciviruses cause hepatitis C virus infections in humans.
  • Other important viral infections caused by the Flaviviridae family include West Nile virus (WNV) Japanese encephalitis virus (JEV), tick-borne encephalitis virus, Junjin virus, Murray Valley encephalitis, St Louis enchaplitis, Omsk hemorrhagic fever virus and Zika virus.
  • WNV West Nile virus
  • JEV Japanese encephalitis virus
  • JEV tick-borne encephalitis virus
  • Junjin virus Junjin virus
  • Murray Valley encephalitis Junjin virus
  • St Louis enchaplitis Omsk hemorrhagic fever virus
  • Zika virus Zika virus
  • HCV hepatitis C virus
  • RNA-dependent RNA polymerase is one of the best studied targets for the development of novel HCV therapeutic agents.
  • the NS5B polymerase is a target for inhibitors in early human clinical trials ( Sommadossi, J., WO 01/90121 A2 , US 2004/0006002 A1 ). These enzymes have been extensively characterized at the biochemical and structural level, with screening assays for identifying selective inhibitors ( De Clercq, E. (2001) J. Pharmacol. Exp.Ther. 297:1-10 ; De Clercq, E. (2001) J. Clin. Virol. 22:73-89 ). Biochemical targets such as NS5B are important in developing HCV therapies since HCV does not replicate in the laboratory and there are difficulties in developing cell-based assays and preclinical animal systems.
  • ribavirin a nucleoside analog
  • IFN interferon-alpha
  • Ribavirin alone is not effective in reducing viral RNA levels, has significant toxicity, and is known to induce anemia.
  • the combination of IFN and ribavirin has been reported to be effective in the management of chronic hepatitis C ( Scott, L. J., et al. Drugs 2002, 62, 507-556 ) but less than half the patients infected with some genotypes show a persistent benefit when given this treatment.
  • Virologic cures of patients with chronic HCV infection are difficult to achieve because of the prodigous amount of daily virus production in chronically infected patients and the high spontaneous mutability of HCV virus ( Neumann, et al., Science 1998, 282, 103-7 ; Fukimoto, et al., Hepatology, 1996, 24, 1351-4 ; Domingo, et al., Gene, 1985, 40, 1-8 ; Martell, et al., J. Virol. 1992, 66, 3225-9 .
  • Experimental anti-viral nucleoside analogs have been shown to induce vialable mutations in the HCV virus both in vivo and in vitro ( Migliaccio, et al., J. Biol. Chem.
  • Certain ribosides of the nucleobases pyrrolo[1,2-f][1,2,4]triazine, imidazo[1,5-f][1,2,4]triazine, imidazo[1,2-f][1,2,4]triazine, and [1,2,4]triazolo[4,3-f][1,2,4]triazine have been disclosed in Carbohydrate Research 2001, 331(1), 77-82 ; Nucleosides & Nucleotides (1996), 15(1-3), 793-807 ; Tetrahedron Letters (1994), 35(30), 5339-42 ; Heterocycles (1992), 34(3), 569-74 ; J. Chem. Soc. Perkin Trans.
  • Ribosides of pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleobases with antiviral, anti-HCV, and anti-RdRp activity have been disclosed by Babu, Y. S., WO2008/089105 and WO2008/141079 ; Cho, et al., WO2009/132123 and Francom, et al. WO2010/002877 .
  • the invention is defined in the appended claims. Any disclosure, including described as being part of the invention but falling outside the scope of said claims, is only intended for illustrative purposes.
  • the invention also comprises compounds of Formula I that inhibit viral nucleic acid polymerases, particularly HCV RNA-dependent RNA polymerase (RdRp), rather than cellular nucleic acid polymerases.
  • RdRp HCV RNA-dependent RNA polymerase
  • the compounds of Formula I have been discovered to be efficacious against both wild type and S282T mutant strains of HCV virus. Therefore, a compound of Formula I is useful for treating Flaviviridae infections in humans and other animals.
  • novel compounds of Formula I with activity against infectious Flaviviridae viruses.
  • the compounds of the invention may inhibit viral RNA-dependent RNA polymerase and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human virus such as hepatitis C.
  • compositions comprising an effective amount of a Formula 1 compound, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
  • the present application provides for combination pharmaceutical agent comprising:
  • the present application provides for a method of inhibiting HCV polymerase, comprising contacting a cell infected with HCV with an effective amount of a compound of Formula I; or a pharmaceutically acceptable salts, solvate, and/or ester thereof.
  • the present application provides for a method of inhibiting HCV polymerase, comprising contacting a cell infected with HCV with an effective amount of a compound of Formula I; or a pharmaceutically acceptable salts, solvate, and/or ester thereof; and at least one additional therapeutic agent.
  • the present application provides for a method of treating and/or preventing a disease caused by a viral infection wherein the viral infection is caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Junjin virus, Murray Valley encephalitis virus, St Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral disarrhea virus, Zika virus and Hepatitis C virus; by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Junjin virus, Murray Valley encephalitis virus, St Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral disarrhea virus, Zika virus and Hepatitis C virus
  • the present application provides for a method of treating HCV in a patient, comprising administering to said patient a therapeutically effective amount of a compound of Formula I; or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides for a method of treating HCV in a patient, comprising administering to said patient a therapeutically effective amount of a compound of Formula I; or a pharmaceutically acceptable salt, solvate, and/or ester thereof; and at least one additional therapeutic agent.
  • Another aspect of the invention provides a method for the treatment or prevention of the symptoms or effects of an HCV infection in an infected animal which comprises administering to, i.e. treating, said animal with a pharmaceutical combination composition or formulation comprising an effective amount of a Formula I compound, and a second compound having anti-HCV properties.
  • the invention also provides a method of inhibiting HCV, comprising administering to a mammal infected with HCV an amount of a Formula I compound, effective to inhibit the replication of HCV in infected cells in said mammal.
  • a compound of Formula I for the manufacture of a medicament for the treatment of Flaviviridae viral infections.
  • a compound of Formula I for use in treating a Flaviviridae viral infection is acute or chronic HCV infection.
  • the treatment results in the reduction of one or more of the viral loads or clearance of RNA in the patient.
  • the invention also provides processes and novel intermediates disclosed herein which are useful for preparing Formula I compounds of the invention.
  • novel methods for synthesis, analysis, separation, isolation, purification, characterization, and testing of the compounds of this invention are provided.
  • R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 1 is methyl, CH 2 F, or ethynyl. In another aspect of this embodiment, R 1 is methyl. In another aspect of this embodiment, R 1 is (C 1 -C 8 )alkyl and R 6 is H. In another aspect of this embodiment, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 .
  • R 3 is H, OR a , N(R a ) 2 , N 3 , CN, SR a , halogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl or (C 2 -C 8 )alkynyl.
  • R 3 is H.
  • R 3 is and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 3 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 3 is H and R 1 is (C 1 -C 8 )alkyl.
  • R 3 is H and R 1 methyl, CH 2 F, or ethynyl. In another aspect of this embodiment, R 3 is H and R 1 is methyl. In another aspect of this embodiment, R 3 is H, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 3 is H, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 3 is H, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 3 is H, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 3 is H, R 1 is methyl and R 6 is H.
  • R 4 is H, OR a , N(R a ) 2 , N 3 , CN, SR a , halogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is H. In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • R 5 is H, OR a , N(R a ) 2 , N 3 , CN, SR a , halogen, (C 1 -C 8 )alkyl, (C 2 -C 3 )alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3
  • R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3
  • R 4 is OH, R 1 is methyl and R 6 is H.
  • R 5 is N 3 .
  • R 5 is H.
  • R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl.
  • R 4 is OR a and R 1 is methyl.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H. In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • R 6 is H, CN, OR a or CH 3 .
  • R 6 is H.
  • R 6 is CN.
  • R 6 is OR a .
  • R 6 is OH.
  • R 6 is CH 3 .
  • R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is H. In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • R 6 is CN, OR a or CH 3 . In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR a . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a . In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a . In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • X 1 is N or C-R 10 . In another aspect of this embodiment, X 1 is N. In another aspect of this embodiment, X 1 is C-R 10 . In another aspect of this embodiment, X 2 is C-H. In another aspect of this embodiment, X 1 is N and X 2 is C-H. In another aspect of this embodiment, X 1 is C-R 10 and X 2 is CH. In another aspect of this embodiment R 6 is H. In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR a . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl.
  • R 4 is OR a and R 1 is methyl.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • each R 8 is independently halogen, NR 11 R 12 , N(R 11 )OR 11 , NR 11 NR 11 R 12 , OR 11 or SR 11 .
  • R 1 is methyl, CH 2 F or ethynyl.
  • R 1 is methyl.
  • R 9 is H, halogen, or NR 11 R 12 .
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl, CH 2 F, or ethynyl.
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl.
  • R 8 is NH 2 and R 9 is H or halogen. In another aspect of this embodiment, R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl, CH 2 F, or ethynyl. In another aspect of this embodiment, R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl. In another aspect of this embodiment, R 8 and R 9 are each NH 2 . In another aspect of this embodiment, R 8 and R 9 are each NH 2 and R 1 is methyl. In another aspect of this embodiment, R 8 and R 9 are each NH 2 and R 1 is methyl, CH 2 F or ethynyl.
  • R 8 is OH and R 9 is NH 2 . In another aspect of this embodiment, R 8 is OH, R 9 is NH 2 and R 1 is methyl. In another aspect of this embodiment, R 8 is OH, R 9 is NH 2 and R 1 is methyl, CH 2 F, or ethynyl. In another aspect of this embodiment R 6 is H. In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR a . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 8 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR 8 and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a .
  • R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • each R 10 is, independently, H, halogen, CN or optionally substituted heteroaryl.
  • R 1 is methyl.
  • R 1 is methyl, CH 2 F or ethynyl.
  • R 9 is H, halogen, or NR 11 R 12 .
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl.
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl, CH 2 F, or ethynyl.
  • R 8 is NH 2 and R 9 is H or halogen.
  • R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl. In another aspect of this embodiment, R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl, CH 2 F, or ethynyl. In another aspect of this embodiment, R 8 and R 9 are each NH 2 . In another aspect of this embodiment, R 8 and R 9 are each NH 3 and R 1 is methyl. In another aspect of this embodiment, R 8 and R 9 are each NH 2 and R 1 is methyl, CH 2 F or ethynyl. In another aspect of this embodiment, R 8 is OH and R 9 is NH 2 .
  • R 8 is OH, R 9 is NH 2 and R 1 is methyl. In another aspect of this embodiment, R 8 is OH, R 9 is NH 2 and R 1 is methyl, CH 2 F, or ethynyl. In another aspect of this embodiment R 6 is H. In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR a . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a .
  • R 4 is OR a and R 1 is (C 1 -C 8 )alkyl, (C 2 -C 8 ) alkenyl or (C 2 -C 3 )alkynyl. In another aspect of this embodiment, R 4 is OR a and R 1 is (C 1 -C 8 )alkyl. In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR 1 . R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is (C 1 -C 8 )alkyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is (C 1 -C 8 )alkyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • compounds of Formula I or Formula II are represented by Formula III: or a pharmaceutically acceptable salt, thereof; wherein: R 1 is CH 3 , CH 2 F, or ethynyl and all remaining variables are defined as for Formula I.
  • R 4 is H, OR a , N(R a ) 2 , N 3 , CN, SR a , halogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl or (C 2 -C 8 )alkynyl.
  • R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is CH 3 , CH 2 F, or ethynyl.
  • R 4 is OR a and R 1 is methyl.
  • R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OH, R 1 is methyl and R 6 is II.
  • R 6 is H, CN, OR a or CH 3 .
  • R 6 is H.
  • R 6 is CN.
  • R 6 is OR a .
  • R 6 is OH.
  • R 6 is CH 3 .
  • R 4 is H or OR a .
  • R 4 is OR a .
  • R 4 is OR a and R 1 is methyl.
  • R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OH, R 1 is methyl and R 6 is H.
  • R 6 is CN, OR a or CH 3 . In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR a . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a . In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is H. In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • X 1 is N or C-R 10 . In another aspect of this embodiment, X 1 is N. In another aspect of this embodiment, X 1 is C-R 10 . In another aspect of this embodiment, X 2 is C-H. In another aspect of this embodiment, X 1 is N and X 2 is C-H. In another aspect of this embodiment, X 1 is C-R 10 and X 2 is CH. In another aspect of this embodiment R 6 is H. In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR 1 . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a .
  • R 4 is OR a . In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH and R 1 is methyl. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N. In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 . In another aspect of this embodiment, R 4 is OH, R 1 is methyl and R 6 is H.
  • each R 8 is independently halogen, NR 11 R 12 , N(R 11 )OR 11 , NR 11 NR 11 R 12 , OR 11 or SR 11 .
  • R 1 is methyl, CH 2 F or ethynyl.
  • R 1 is methyl.
  • R 9 is H, halogen, or NR 11 R 12 .
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl, CH 2 F, or ethynyl.
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl.
  • R 8 is NH 2 and R 9 is H or halogen. In another aspect of this embodiment, R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl, CH 2 F, or ethynyl. In another aspect of this embodiment, R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl. In another aspect of this embodiment, R 8 and R 9 are each NH 2 . In another aspect of this embodiment, R 8 and R 9 are each NH 2 and R 1 is methyl, CH 2 F or ethynyl. In another aspect of this embodiment, R 8 and R 9 are each NH 2 and R 1 is methyl.
  • R 8 is OH and R 9 is NH 2 .
  • R 8 is OH, R 9 is NH 2 and R 1 is methyl, CH 2 F, or ethynyl.
  • R 8 is OH, R 9 is NH 2 and R 1 is methyl.
  • R 6 is H.
  • R 6 is CN.
  • R 6 is OR a .
  • R 6 is OH.
  • R 6 is CH 3 .
  • R 4 is H or OR a .
  • R 4 is OR a and R 1 is methyl.
  • R 4 is OR a , R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is melhyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OH, R 1 is methyl and R 6 is H.
  • each R 10 is, independently, H, halogen, CN or optionally substituted heteroaryl.
  • R 1 is methyl.
  • R 9 is H, halogen, or NR 11 R 12 .
  • R 9 is H, halogen, or NR 11 R 12 and R 1 is methyl.
  • R 8 is NH 2 and R 9 is H or halogen.
  • R 8 is NH 2 and R 9 is H or halogen and R 1 is methyl.
  • R 8 and R 9 are each NH 2 .
  • R 8 and R 9 are each NH 2 and R 1 is methyl.
  • R 8 is OH and R 9 is NH 2 . In another aspect of this embodiment, R 8 is OH, R 9 is NH 2 and R 1 is methyl. In another aspect of this embodiment R 6 is H. In another aspect of this embodiment R 6 is CN. In another aspect of this embodiment R 6 is OR a . In another aspect of this embodiment R 6 is OH. In another aspect of this embodiment R 6 is CH 3 . In another aspect of this embodiment, R 4 is H or OR a . In another aspect of this embodiment, R 4 is OR a and R 1 is methyl. In another aspect of this embodiment, R 4 is OR a . R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OR a , R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OR a , R 1 is methyl and R 6 is H.
  • R 4 is OH and R 1 is methyl.
  • R 4 is OH, R 1 is methyl and at least one of X 1 or X 2 is N.
  • R 4 is OH, R 1 is methyl and R 6 is CN, OH, or CH 3 .
  • R 4 is OH, R 1 is methyl and R 6 is H.
  • R 11 and R 12 taken together with a nitrogen to which they are both attached, form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -O-, -S- or -NR a -. Therefore, by way of example and not limitation, the moiety - NR 11 R 12 can be represented by the heterocycles:
  • each R 3 , R 4 , R 5 , R 6 , R 11 or R 12 is, independently, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl or aryl(C 1 -C 8 )alkyl, wherein said (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl or aryl(C 1 -C 8 )alkyl are, independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R a ) 2 or OR a .
  • R 3 , R 4 , R 5 , R 6 , R 11 or R 12 could represent moieties such as -CH(NH 2 )CH 3 , -CH(OH)CH2CH3,-CH(NH 2 )CH(CH 3 ) 2 , -CH 2 CF 3 , -(CH 2 ) 2 CH(N 3 )CH 3 , -(CH 2 ) 6 NH 2 .
  • R 3 , R 4 , R 5 , R 6 , R 11 or R 12 is (C 1 -C 8 )alkyl wherein one or more of the non-terminal carbon atoms of each said (C 1 -C 8 )alkyl may be optionally replaced with -O-, -S- or -NR a -.
  • R 3 , R 4 , R 5 , R 6 , R 11 or R 12 could represent moieties such as -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , -CH 2 OCH(CH 3 ) 2 , -CH 2 SCH 3 , -(CH 2 ) 6 OCH 3 ,-(CH 2 ) 6 N(CH 3 ) 2 .
  • Formulas I-III is a compound selected from the group consisting of and or a pharmaceutically acceptable salt or ester thereof.
  • a compound useful for the synthesis of the compounds of Formula I selected from the group consisting of or salts or esters thereof.
  • a compound of the invention or "a compound of Formula I” means a compound of Formula I or a pharmaceutically acceptable salt, thereof.
  • a compound of Formula (number) means a compound of that formula and pharmaceutically acceptable salts, thereof.
  • Alkyl is hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms.
  • an alkyl group can have 1 to 20 carbon atoms ( i.e , C 1 -C 20 alkyl), 1 to 8 carbon atoms ( i.e ., C 1 -C 8 alkyl), or 1 to 6 carbon atoms ( i.e. , C 1 -C 6 alkyl).
  • alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl ( n -Pr, n -propyl, -CH 2 CH 2 CH 3 ), 2-propyl ( i -Pr, i -propyl, -CH(CH 3 ) 2 ), 1-butyl ( n -Bu, n -butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl ( i -Bu, i- butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl ( s -Bu, s -butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl ( t -Bu, t -butyl, -C(CH 3 ) 3 ), 1-pentyl ( n -pentyl, -CH 2
  • Alkoxy means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
  • the alkyl portion of an alkoxy group can have 1 to 20 carbon atoms ( i.e ., C 1 -C 20 alkoxy), 1 to 12 carbon atoms ( i.e ., C 1 -C 12 alkoxy), or 1 to 6 carbon atoms ( i.e. , C 1 -C 6 alkoxy).
  • alkoxy groups include, but are not limited to, methoxy (-O-CH 3 or -OMe), ethoxy (-OCH 2 CH 3 or -OEt), t-butoxy (-O-C(CH 3 ) 3 or -OtBu).
  • Haloalkyl is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom.
  • the alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms ( i.e ., C 1 -C 20 haloalkyl), 1 to 12 carbon atoms ( i.e ., C 1 -C 12 haloalkyl), or 1 to 6 carbon atoms ( i.e ., C 1 -C 6 alkyl).
  • suitable haloalkyl groups include, but are not limited to, -CF 3 , -CHF 2 , -CFH 2 , -CH 2 CF 3 .
  • Alkenyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp 2 double bond.
  • an alkenyl group can have 2 to 20 carbon atoms ( i.e. , C 2 -C 20 alkenyl), 2 to 8 carbon atoms ( i.e. , C 2 -C 8 alkenyl), or 2 to 6 carbon atoms ( i.e. , C 2 -C 6 alkenyl).
  • Alkynyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e . a carbon-carbon, sp triple bond.
  • an alkynyl group can have 2 to 20 carbon atoms ( i.e. , C 2 -C 20 alkynyl), 2 to 8 carbon atoms ( i.e., C 2 -C 8 alkyne,), or 2 to 6 carbon atoms ( i.e. , C 2 -C 6 alkynyl).
  • suitable alkynyl groups include, but are not limited to, acetylenic (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH).
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • an alkylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkylene radicals include, but are not limited to, methylene (-CH 2 -), 1,1-ethyl (-CH(CH 3 )-), 1,2-ethyl (-CH 2 CH 2 -), 1,1-propyl (-CH(CH 2 CH 3 )-), 1,2-propyl (-CH 2 CH(CH 3 )-), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -).
  • alkenylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkenylene radicals include, but are not limited to, 1,2-ethylene (-CH ⁇ CH-).
  • Alkynylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • an alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkynylene radicals include, but are not limited to, acetylene (-C ⁇ C-), propargyl (-CH 2 C ⁇ C-), and 4-pentynyl (-CH 2 CH 2 CH 2 C ⁇ C-).
  • Ammonia refers generally to a nitrogen radical which can be considered a derivative of ammonia, having the formula-N(X) 2 , where each "X” is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, etc.
  • the hybridization of the nitrogen is approximately sp 3 .
  • Nonlimiting types of amino include -NH 2 , -N(alkyl) 2 , -NH(alkyl), -N(carbocyclyl) 2 ,-NH(carbocyclyl), -N(heterucyclyl) 2 , -NH(heterocyclyl), -N(aryl) 2 , -NH(aryl),-N(alkyl)(aryl), -N(alkyl)(heterocyelyl), -N(carbocyclyl)(heterocyclyl),-N(aryl)(heteroaryl), -N(alkyl)(heteroaryl), etc.
  • alkylamino refers to an amino group substituted with at least one alkyl group.
  • Nonlimiting examples of amino groups include -NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -NH(CH 2 CH 3 ), - N(CH 2 CH 3 ) 2 ,-NH(phenyl), -N(phenyl) 2 , -NH(benzyl), -N(benzyl) 2 , etc.
  • Substituted alkylamino refers generally to alkylamino groups, as defined above, in which at least one substituted alkyl, as defined herein, is attached to the amino nitrogen atom.
  • Non-limiting examples of substituted alkylamino includes -NH(alkylene-C(O)-OH), -NH(alkylene-C(O)-O-alkyl), -N(alkylene-C(O)-OH) 2 , -N(alkylene-C(O)-O-alkyl) 2 , etc.
  • Aryl means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl.
  • Arylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl radical.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl.
  • the arylalkyl group can comprise 7 to 20 carbon atoms, e.g. , the alkyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp 2 carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkenyl can include, for example, any of the aryl groups disclosed herein, and the alkenyl portion of the arylalkenyl can include, for example, any of the alkenyl groups disclosed herein.
  • the arylalkenyl group can comprise 8 to 20 carbon atoms, e.g., the alkenyl moiety is 2 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkynyl can include, for example, any of the aryl groups disclosed herein, and the alkynyl portion of the arylalkynyl can include, for example, any of the alkynyl groups disclosed herein.
  • the arylalkynyl group can comprise 8 to 20 carbon atoms, e.g., the alkynyl moiety is 2 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • substituted in reference to alkyl, alkylene, aryl, arylalkyl, alkoxy, heterocyclyl, heteroaryl, carbocyclyl, etc., for example, “substituted alkyl”, “substituted alkylene”, “substituted aryl”, “substituted arylalkyl”, “substituted heterocyclyl”, and “substituted carbocyclyl”, unless otherwise indicated, means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
  • Alkylene, alkenylene, and alkynylene groups may also be similarly substituted. Unless otherwise indicated, when the term "substituted" is used in conjunction with groups such as arylalkyl, which have two or more moieties capable of substitution, the substituents can be attached to the aryl moiety, the alkyl moiety, or both.
  • prodrug refers to any compound that when administered to a biological system generates the drug substance, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s).
  • a prodrug is thus a covalently modified analog or latent form of a therapeutically active compound.
  • substituents and other moieties of the compounds of Formula I-III should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition.
  • the definitions and substituents for various genus and subgenus of the present compounds are described and illustrated herein. It should be understood by one skilled in the art that any combination of the definitions and substituents described above should not result in an inoperable species or compound.
  • "Inoperable species or compounds” means compound structures that violates relevant scientific principles (such as, for example, a carbon atom connecting to more than four covalent bonds) or compounds too unstable to permit isolation and formulation into pharmaceutically acceptable dosage forms.
  • Heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • a heteroatom e.g., O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH 3 , etc.), an amine (e.g., -NHCH 3 , -N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., -SCH 3 ).
  • the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH 2 CH 2 -O-CH 3 , etc.), an alkyl amine (e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.), or a thioalkyl ether (e.g.,-CH 2 -S-CH 3 ).
  • an alkyl ether e.g., -CH 2 CH 2 -O-CH 3 , etc.
  • an alkyl amine e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.
  • a thioalkyl ether e.g.,-CH 2 -S-CH 3
  • the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH 2 CH 2 -OH), an aminoalkyl group (e.g., -CH 2 NH 2 ), or an alkyl thiol group (e.g., -CH 2 CH 2 -SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a C 1 -C 6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • Heterocycle or “heterocyclyl” as used herein includes by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968 ), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs” (John Wiley & Sons, New York, 1950 to present ), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566 .
  • heterocycle includes a "carbocycle” as defined herein, wherein one or more ( e.g.
  • heterocycle or “heterocyclyl” includes saturated rings, partially unsaturated rings, and aromatic rings ( i.e ., heteroaromatic rings).
  • Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
  • a non-limiting example of a carbonyl substituted heterocyclyl is:
  • heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2,4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidinc, 2-imidazolinc, 3-imidazolinc, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • Heterocyclylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heterocyclyl radical (i.e ., a heterocyclyl-alkylene- moiety).
  • Typical heterocyclyl alkyl groups include, but are not limited to heterocyclyl-CH 2 -, 2-(heterocyclyl)ethan-1-yl, wherein the "heterocyclyl” portion includes any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry .
  • heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkyl group comprises 3 to 20 carbon atoms, e.g. , the alkyl portion of the arylalkyl group is 1 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
  • heterocyclylalkyls include by way of example and not limitation 5-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as thiazolylmethyl, 2-thiazolylethan-1-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
  • heterocycles such as thiazolylmethyl, 2-thiazolylethan-1-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc.
  • 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl,
  • Heterocyclylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also a sp 2 carbon atom, is replaced with a heterocyclyl radical (i.e. , a heterocyclyl-alkenylene- moiety).
  • the heterocyclyl portion of the heterocyclyl alkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry , and the alkenyl portion of the heterocyclyl alkenyl group includes any of the alkenyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkenyl portion of the heterocyclyl alkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkenyl group comprises 4 to 20 carbon atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
  • Heterocyclylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkynylene- moiety).
  • the heterocyclyl portion of the heterocyclyl alkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry , and the alkynyl portion of the heterocyclyl alkynyl group includes any of the alkynyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkynyl portion of the heterocyclyl alkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkynyl group comprises 4 to 20 carbon atoms, e.g., the alkynyl portion of the heterocyclyl alkynyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
  • Heteroaryl refers to an aromatic heterocyclyl having at least one heteroatom in the ring.
  • suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen.
  • Non-limiting examples of heteroaryl rings include all of those aromatic rings listed in the definition of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
  • Carbocycle or “carbocyclyl” refers to a saturated (i.e., cycloalkyl), partially unsaturated (e.g., cycloakenyl, cycloalkadienyl, etc.) or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
  • Monocyclic carbocycles have 3 to 7 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g.
  • Non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, l-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, l-cyclohex-3-enyl, and phenyl.
  • Non-limiting examples of bicyclo carbocycles includes naphthyl, tetrahydronapthalene, and decaline.
  • Carbocyclylalkyl refers to to an acyclic akyl radical in which one of the hydrogen atoms bonded to a carbon atom is replaced with a carbocyclyl radical as described herein.
  • Typical, but non-limiting, examples of carbocyclylalkyl groups include cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.
  • Arylhetemalkyl refers to a heteroalkyl as defined herein, in which a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced with an aryl group as defined herein.
  • the aryl groups may be bonded to a carbon atom of the heteroalkyl group, or to a heteroatom of the heteroalkyl group, provided that the resulting arylheteroalkyl group provides a chemically stable moiety.
  • an arylheteroalkyl group can have the general formulae -alkylene-O-aryl, -alkylene-O-alkylene-aryl, -alkylene-NH-aryl, -alkylene-NH-alkylene-aryl, -alkylene-S-aryl, -alkylene-S-alkylene-aryl, etc.
  • any of the alkylene moieties in the general formulae above can be further substituted with any of the substituents defined or exemplified herein.
  • Heteroarylalkyl refers to an alkyl group, as defined herein, in which a hydrogen atom has been replaced with a heteroaryl group as defined herein.
  • Non-limiting examples of heteroaryl alkyl include -CH 2 -pyridinyl, -CH 2 -pyrrolyl, -CH 2 -oxazolyl, -CH 2 -indolyl, -CH 2 -isoindolyl, -CH 2 -purinyl, -CH 2 -furanyl, -CH 2 -thienyl, -CH 2 -benzofuranyl, -CH 2 -benzothiophenyl, -CH 2 -carbazolyl, -CH 2 -imidazolyl, -CH 2 -thiazolyl, -CH 2 -isoxazolyl, -CH 2 -pyrazolyl, -CH 2 -isothiazolyl, -CH 2
  • optionally substituted in reference to a particular moiety of the compound of Formula I-III (e.g., an optionally substituted aryl group) refers to a moiety wherein all substiutents are hydrogen or wherein one or more of the hydrogens of the moiety may be replaced by substituents such as those listed under the definition of "substituted” or as otherwise indicated.
  • the term "optionally replaced" in reference to a particular moiety of the compound of Formula I-III e.g., the carbon atoms of said (C 1 -C 8 )alkyl may be optionally replaced by -O - , -S-, or -NR a -) means that one or more of the methylene groups of the (C 1 -C 8 )alkyl may be replaced by 0, 1, 2, or more of the groups specified (e.g., -O - , -S-, or -NR a -).
  • non-terminal carbon atom(s) in reference to an alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene moiety refers to the carbon atoms in the moiety that intervene between the first carbon atom of the moiety and the last carbon atom in the moiety. Therefore, by way of example and not limitation, in the alkyl moiety -CH 2 (C*)H 2 (C*)H 2 CH 3 or alkylene moiety -CH 2 (C*)H 2 (C*)H 2 CH 2 - the C* atoms would be considered to be the non-terminal carbon atoms.
  • Certain Y and Y 1 alternatives are nitrogen oxides such as + N(O)(R) or + N(O)(OR). These nitrogen oxides, as shown here attached to a carbon atom, can also be represented by charge separated groups such as respectively, and are intended to be equivalent to the aforementioned representations for the purposes of describing this invention.
  • Linker or “link” means a chemical moiety comprising a covalent bond or a chain of atoms.
  • Linkers include repeating units of alkyloxy (e.g. polyethyleneoxy, PEG, polymethyleneoxy) and alkylamino (e.g. polyethyleneamino, JeffamineTM); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide.
  • oxygen-linked means that if a bond between two moieties can be formed by using more than one type of atom in a moiety, then the bond formed between the moieties is through the atom specified.
  • a nitrogen-linked amino acid would be bonded through a nitrogen atom of the amino acid rather than through an oxygen or carbon atom of the amino acid.
  • the carbon atoms of the compounds of Formula I-III are intended to have a valence of four.
  • the remaining carbon substitutents needed to provide a valence of four should be assumed to be hydrogen. For example, has the same meaning as
  • Protecting group refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole.
  • the chemical substructure of a protecting group varies widely.
  • One function of a protecting group is to serve as an intermediate in the synthesis of the parental drug substance.
  • Chemical protecting groups and strategies for protection/deprotection are well known in the art. See: “ Protective Groups in Organic Chemistry", Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991 .
  • Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g. making and breaking chemical bonds in an ordered and planned fashion.
  • Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools.
  • Chemically protected intermediates may themselves be biologically active or inactive.
  • Protected compounds may also exhibit altered, and in some cases, optimized properties in vitro and in vivo, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs.
  • Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency in vivo than the parental drug.
  • Protecting groups are removed either in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g. alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.
  • Prodrug moiety means a labile functional group which separates from the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process ( Bundgaard, Hans, “Design and Application of Prodrugs” in Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 113-191 ).
  • Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphases.
  • Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to optimize drug delivery, bioavailability and efficacy.
  • a prodrug moiety may include an active metabolite or drug itself.
  • the acyloxyalkyl ester was used as a prodrug strategy for carboxylic acids and then applied to phosphates and phosphonates by Farquhar et al (1983) J. Pharm. Sci. 72: 324 ; also US Patent Nos.
  • a prodrug moiety is part of a phosphate group.
  • the acyloxyalkyl ester may be used to deliver phosphoric acids across cell membranes and to enhance oral bioavailability.
  • a close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester (carbonate), may also enhance oral bioavailability as a prodrug moiety in the compounds of the combinations of the invention.
  • the phosphate group may be a phosphate prodrug moiety.
  • the prodrug moiety may be sensitive to hydrolysis, such as, but not limited to those comprising a pivaloyloxymethyl carbonate (POC) or POM group.
  • the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphonamidate-ester group.
  • Aryl esters of phosphorus groups are reported to enhance oral bioavailability ( DeLambert et al (1994) J. Med. Chem. 37: 498 ). Phenyl esters containing a carboxylic ester ortho to the phosphate have also been described ( Khamnei and Torrence, (1996) J. Med. Chem. 39:4109-4115 ). Benzyl esters are reported to generate the parent phosphonic acid. In some cases, substituents at the ortho- or p ⁇ ra- position may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of enzymes, e.g.
  • proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined with another thiol group to form a disulfide. Dccstcrification or reduction of the disulfide generates the free thio intermediate which subsequently breaks down to the phosphoric acid and episulfide ( Puech et al (1993) Antiviral Res., 22: 155-174 ; Benzaria et al (1996) J. Med. Chem. 39: 4958 ). Cyclic phosphonate esters have also been described as prodrugs of phosphorus-containing compounds ( Erion et al, US Patent No. 6312662 ).
  • a compound of Formula I-III and its pharmaceutically acceptable salts may exist as different polymorphs or pseudopolymorphs.
  • crystalline polymorphism means the ability of a crystalline compound to exist in different crystal structures. The crystalline polymorphism may result from differences in crystal packing (packing polymorphism) or differences in packing between different conformers of the same molecule (conformational polymorphism).
  • crystalline pseudopolymorphism means the ability of a hydrate or solvate of a compound to exist in different crystal structures.
  • the pseudopolymorphs of the instant invention may exist due to differences in crystal packing (packing pseudopolymorphism) or due to differences in packing between different conformers of the same molecule (conformational pseudopolymorphism).
  • the instant invention comprises all polymorphs and pseudopolymorphs of the compounds of Formula I-III and their pharmaceutically acceptable salts.
  • a compound of Formula I-III and its pharmaceutically acceptable salts may also exist as an amorphous solid.
  • an amorphous solid is a solid in which there is no long-range order of the positions of the atoms in the solid. This definition applies as well when the crystal size is two nanometers or less.
  • Additives, including solvents, may be used to create the amorphous forms of the instant invention.
  • the instant invention comprises all amorphous forms of the compounds of Formula I-III and their pharmaccutically acceptable salts.
  • R x comprises a R y substituent.
  • R y can be R.
  • R can be W 3 .
  • W 3 can be W 4 and W 4 can be R or comprise substituents comprising R y .
  • One of ordinary skill in the art of medicinal chemistry understands that the total number of such substituents is reasonably limited by the desired properties of the compound intended. Such properties include, by way of example and not limitation, physical properties such as molecular weight, solubility or log P, application properties such as activity against the intended target, and practical properties such as ease of synthesis.
  • W 3 and R y are recursive substituents in certain embodiments.
  • each recursive substituent can independently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, times in a given embodiment.
  • each recursive substituent can independently occur 12 or fewer times in a given embodiment.
  • each recursive substituent can independently occur 3 or fewer times in a given embodiment.
  • W 3 will occur 0 to 8 times
  • R y will occur 0 to 6 times in a given embodiment.
  • W 3 will occur 0 to 6 times and R y will occur 0 to 4 times in a given embodiment.
  • Recursive substituents are an intended aspect of the invention.
  • One of ordinary skill in the art of medicinal chemistry understands the versatility of such substituents.
  • the compounds of the Formula I-III may comprise a phosphate group as R 7 .
  • R 7 which may be a prodrug moiety wherein each Y or Y 1 is, independently, O, S, NR, + N(O)(R), N(OR), + N(O)(OR), or N-NR 2 ; W 1 and W 2 , when taken together, are -Y 3 (C(R y ) 2 ) 3 Y 3 -; or one of W 1 or W 2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W 2 is Formula Ia; or W 1 and W 2 are each, independently, a group of Formula Ia: wherein:
  • W 3 carbocycles and W 5 heterocycles may be independently substituted with 0 to 3 R y groups.
  • W 5 may be a saturated, unsaturated or aromatic ring comprising a mono- or bicyclic carbocycle or heterocycle.
  • W 5 may have 3 to 10 ring atoms, e.g., 3 to 7 ring atoms.
  • the W 5 rings are saturated when containing 3 ring atoms, saturated or mono-unsaturated when containing 4 ring atoms, saturated, or mono- or di-unsaturated when containing 5 ring atoms, and saturated, mono- or di-unsaturaled, or aromatic when containing 6 ring atoms.
  • a W 5 heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S).
  • W 5 heterocyclic monocycles may have 3 to 6 ring atoms (2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S); or 5 or 6 ring atoms (3 to 5 carbon atoms and 1 to 2 heteroatoms selected from N and S).
  • W 5 heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S) arranged as a bicyclo [4,5], [5,5], [5,6], or [6,6] system; or 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2 hetero atoms selected from N and S) arranged as a bicyclo [5,6] or [6,6] system.
  • the W 5 heterocycle may be bonded to Y 2 through a carbon, nitrogen, sulfur or other atom by a stable covalent bond.
  • W 5 heterocycles include for example, pyridyl, dihydropyridyl isomers, piperidine, pyridazinyl, pyrimidinyl, pyrazinyl, s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and pyrrolyl.
  • W 5 also includes, but is not limited to, examples such as:
  • W 5 carbocycles and heterocycles may be independently substituted with 0 to 3 R groups, as defined above.
  • substituted W 5 carbocycles include:
  • substituted phenyl carbocycles include:
  • Embodiments of of Formula I-III compounds include substructures such as: wherein each Y 2b is, independently, O or N(R). In another aspect of this embodiment, each Y 2b is O and each R x is independently: wherein M12c is 1, 2 or 3 and each Y 2 is independently a bond, O, CR 2 , or S. In another aspect of this embodiment, one Y 2b -R x is NH(R) and the other Y 2b -R x is O-R x wherein R x is: wherein M12c is 2. In another aspect of this embodiment, each Y 2b is O and each R x is independently: wherein M12c is 2. In another aspect of this embodiment, each Y 2b is O and each R x is independently: wherein M12c is 1 and Y 2 is a bond, O, or CR 2 .
  • each Y 3 is, independently, O or N(R). In another aspect of this embodiment, each Y 3 is O. In another aspect of this embodiment, the substructure is: wherein R y is W 5 as defined herein.
  • Another embodiment of of Formula I-III includes the substructures: wherein each Y 2c is, independently, O, N(R y ) or S.
  • Another embodiment of of Formula I-III compounds includes the substructures wherein one of W 1 or W 2 together with either R 3 or R 4 is-Y 3 - and the other of W 1 or W 2 is Formula Ia.
  • Such an embodiment is represented by a compound of Formula Ib selected from: or
  • each Y and Y 3 is O.
  • W 1 or W 2 is Y 2b -R x ; each Y, Y 3 and Y 2b is O and R x is: wherein M12c is 1, 2 or 3 and each Y 2 is independently a bond, O, CR 2 , or S.
  • W 1 or W 2 is Y 2b -R x ; each Y, Y 3 and Y 2b is O and R x is: wherein M12c is 2.
  • W 1 or W 2 is Y 2b -R x ; each Y, Y 3 and Y 2b is O and R x is: wherein M12c is 1 and Y 2 is a bond, O, or CR 2 .
  • Another embodiment of of Formula I-III compounds includes a substructure: wherein W 5 is a carbocycle such as phenyl or substituted phenyl.
  • the substructure is: wherein Y 2b is O or N(R) and the phenyl carbocycle is substituted with 0 to 3 R groups.
  • R x is: wherein M12c is 1, 2 or 3 and each Y 2 is independently a bond, O, CR 2 , or S.
  • Another embodiment of of Formula I-III includes substructure:
  • the chiral carbon of the amino acid and lactate moieties may be either the R or S configuration or the racemic mixture.
  • R y is (C 1 -C 3 ) alkyl, (C 1 -C 8 ) substituted alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl or (C 2 -C 8 ) substituted alkynyl.
  • R y is (C 1 -C 8 ) alkyl, (C 1 -C 8 ) substituted alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl or (C 2 -C 8 ) substituted alkynyl; and R is CH 3 .
  • R y is (C 1 -C 8 ) alkyl, (C 1 -C 8 ) substituted alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl or (C 2 -C 8 ) substituted alkynyl; R is CH 3 ; and each Y 2 is -NH-.
  • W 1 and W 2 are, independently, nitrogen-linked, naturally occurring amino acids or naturally occurring amino acid esters.
  • W 1 and W 2 are, independently, naturally-occurring 2-hydroxy carboxylic acids or naturally-occurring 2-hydroxy carboxylic acid esters wherein the acid or ester is linked to P through the 2-hydroxy group.
  • each R x is, independently, (C 1 -C 8 ) alkyl. In another aspect of this embodiment, each R x is, independently, C 6 -C 20 aryl or C 6 -C 20 substituted aryl.
  • W 1 and W 2 are independently selected from one of the formulas in Tables 20.1-20.37 and Table 30.1 below.
  • the variables used in Tables 20.1-20.37 e.g., W 23 , R 21 , etc.
  • Tables 20.1-20.37 pertain only to Tables 20.1-20.37, unless otherwise indicated.
  • Embodiments of R x include esters, carbamates, carbonates, thioesters, amides, thioamides, and urea groups:
  • any reference to the compounds of the invention described heerein also includes a reference to a physiologically acceptable salt thereof.
  • physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal or an alkaline earth (for example, Na + , Li + , K + , Ca +2 and Mg +2 ), ammonium and NR 4 + (wherein R is defined herein).
  • Physiologically acceptable salts of a nitrogen atom or an amino group include (a) acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acids, phosphoric acid, nitric acid; (b) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic acid, sulfosalicylic acid, glycolic
  • salts of active ingredients of the compounds of the invention will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base.
  • salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.
  • compositions herein comprise compounds of the invention in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
  • the compounds of the invention may have chiral centers, e.g. chiral carbon or phosphorus atoms.
  • the compounds of the invention thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers.
  • the compounds of the invention include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the depictions are provided as the chiral isomers or racemic mixtures.
  • racemic and diastereomeric mixtures are all within the scope of the invention.
  • the racemic mixtures are separated into their individual, substantially optically pure isomers through well-known techniques such as, for example, the separation of diastereomeric salts formed with optically active adjuncts, e.g., acids or bases followed by conversion back to the optically active substances.
  • optically active adjuncts e.g., acids or bases followed by conversion back to the optically active substances.
  • the desired optical isomer is synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • racemic mixture A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • racemic mixture and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • the compounds of the invention can also exist as tautomeric isomers in certain cases. Although only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the invention.
  • ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole systems and all their possible tautomeric forms are within the scope of the invention.
  • pyrrolo[1,2-f][1,2,4]triazine, imidazo[1,5-f][1,2,4]triazine, imidazo[1,2-f][1,2,4]triazine, and [1,2,4]triazolo[4,3-f][1,2,4]triazine nucleosides can exist in tautomeric forms.
  • structures (a) and (b) can have equivalent tautomeric forms as shown below: All possible tautomeric forms of the heterocycles in all of the embodiments disclosed herein are within the scope of the invention.
  • Another aspect of the invention relates to methods of inhibiting the activity of HCV polymerase comprising the step of treating a sample suspected of containing HCV with a composition of the invention.
  • compositions of the invention may act as inhibitors of HCV polymerase, as intermediates for such inhibitors or have other utilities as described below.
  • the inhibitors will bind to locations on the surface or in a cavity of HCV polymerase having a geometry unique to HCV polymerase.
  • Compositions binding HCV polymerase may bind with varying degrees of reversibility. Those compounds binding substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, the substantially irreversibly binding compositions are useful as probes for the detection of HCV polymerase.
  • the invention relates to methods of detecting HCV polymerase in a sample suspected of containing HCV polymerase comprising the steps of: treating a sample suspected of containing HCV polymerase with a composition comprising a compound of the invention bound to a label; and observing the effect of the sample on the activity of the label.
  • Suitable labels are well known in the diagnostics field and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups and chromogens.
  • the compounds herein are labeled in conventional fashion using functional groups such as hydroxyl, carboxyl, sulfhydryl or amino.
  • samples suspected of containing HCV polymerase include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein.
  • biological material samples blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples
  • laboratory samples food, water, or air samples
  • bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein.
  • samples can be contained in any medium including water and organic solvent ⁇ water mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.
  • the treating step of the invention comprises adding the composition of the invention to the sample or it comprises adding a precursor of the composition to the sample.
  • the addition step comprises any method of administration as described above.
  • the activity of HCV polymerase after application of the composition can be observed by any method including direct and indirect methods of detecting HCV polymerase activity. Quantitative, qualitative, and semiquantitative methods of determining HCV polymerase activity are all contemplated. Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.
  • Organisms that contain HCV polymerase include the HCV virus.
  • the compounds of this invention are useful in the treatment or prophylaxis of HCV infections in animals or in man.
  • compositions of the invention are screened for inhibitory activity against HCV polymerase by any of the conventional techniques for evaluating enzyme activity.
  • typically compositions are first screened for inhibition of HCV polymerase in vitro and compositions showing inhibitory activity are then screened for activity in vivo.
  • Compositions having in vitro Ki (inhibitory constants) of less then about 5 X 10 -6 M, typically less than about 1 X 10 -7 M and preferably less than about 5 X 10 -8 M are preferred for in vivo use.
  • the compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice.
  • Tablets will contain excipients, glidants, fillers, binders.
  • Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the " Handbook of Pharmaceutical Excipients" (1986 ). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextran, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid.
  • the pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10.
  • the formulations both for veterinary and for human use, of the invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
  • the formulations include those suitable for the foregoing administration routes.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA ). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be administered as a bolus, electuary or paste.
  • a tablet is made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.
  • the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1 % and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabilizers make up the so-called emulsifying wax
  • the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.
  • compositions according to the present invention comprise a combination according to the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents.
  • Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration.
  • tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
  • excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium phosphate or kaolin
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally-occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate).
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and une or more sweetening agents, such as sucrose or saccharin.
  • Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
  • a dispersing or wetting agent e.g., sodium tartrate
  • suspending agent e.g., sodium EDTA
  • preservatives e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally-occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic
  • a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight:weight).
  • the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
  • an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10%, and particularly about 1.5% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns, such as 0.5, 1, 30, 35 etc., which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable formulations include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of HCV infections as described below.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations arc presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefor.
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
  • controlled release formulations in which the release of the active ingredient are controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given active ingredient.
  • Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active viral infection, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. It can be expected to be from about 0.0001 to about 100 mg/kg body weight per day; typically, from about 0.01 to about 10 mg/kg body weight per day; more typically, from about .01 to about 5 mg/kg body weight per day; most typically, from about .05 to about 0.5 mg/kg body weight per day.
  • the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, preferably between 5 mg and 500 mg, and may take the form of single or multiple doses.
  • One or more compounds of the invention are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural). It will be appreciated that the preferred route may vary with for example the condition of the recipient.
  • An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
  • Combinations of the compounds of Formula I-III are typically selected based on the condition to be treated, cross-reactivities of ingredients and pharmaco-properties of the combination. For example, when treating an infection (e.g., HCV), the compositions of the invention are combined with other active therapeutic agents (such as those described herein).
  • an infection e.g., HCV
  • other active therapeutic agents such as those described herein.
  • compositions of the invention are also used in combination with one or more other active ingredients.
  • the other active therapeutic ingredients or agents are interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, mevalonate decarboxylase antagonists, antagonists of the renin-angiotensin system, other anti-fibrotic agents, endothelin antagonists, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers or other drugs for treating HCV; or mixtures thereof.
  • one or more compounds of the present invention may be combined with one or more compounds selected from the group consisting of
  • compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or exipient.
  • the therapeutic agent used in combination with the compound or composition of the present invention can be any agent haying a therapeutic effect when used in combination with the compound of the present invention.
  • the therapeutic agent used in combination with the compound or composition of the present invention can be interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, mevalonate decarboxylase antagonists, antagonists of the renin-angiotensin system, other anti-fibrotic agents, endothelin antagonists, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers or other drugs for treating HCV; or mixtures thereof.
  • compositions of one or more compounds of the present invention may be combined with one or more compounds selected from the group consisting of
  • the present application provides a combination pharmaceutical agent comprising:
  • Combinations of the compounds of Formula I-III and additional active therapeutic agents may be selected to treat patients infected with HCV and other conditions such as HIV infections.
  • the compounds of Formula I-III may be combined with one or more compounds useful in treating HIV, for example HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.
  • HIV protease inhibiting compounds HIV non-nucleoside inhibitors of reverse transcriptase
  • one or more compounds of the present invention may be combined with one or more compounds selected from the group consisting of 1) HIV protease inhibitors, e.g ., amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, lopinavir + ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), AG1859, DG35, L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100, 2) a HIV non-nucleoside inhibitor of reverse transcriptase, e.g ., capravirine, emivirine, delaviridine, efavirenz, nevirap
  • any compound of the invention with one or more other active therapeutic agents in a unitary dosage form for simultaneous or sequential administration to a patient.
  • the combination therapy may be administered as a simultaneous or sequential regimen.
  • the combination When administered sequentially, the combination may be administered in two or more administrations.
  • Co-administration of a compound of the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound of the invention and one or more other active therapeutic agents, such that therapeutically effective amounts of the compound of the invention and one or more other active therapeutic agents are both present in the body of the patient.
  • Co-administration includes administration of unit dosages of the compounds of the invention before or after administration of unit dosages of one or more other active therapeutic agents, for example, administration of the compounds of the invention within seconds, minutes, or hours of the administration of one or more other active therapeutic agents.
  • a unit dose of a compound of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active therapeutic agents.
  • a unit dose of one or more other therapeutic agents can be administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes.
  • a unit dose of a compound of the invention may be desirable to administer a unit dose of a compound of the invention first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more other active therapeutic agents. In other cases, it may be desirable to administer a unit dose of one or more other active therapeutic agents first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the invention.
  • the combination therapy may provide "synergy” and "synergistic", i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately.
  • a synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
  • a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g. in separate tablets, pills or capsules, or by different injections in separate syringes.
  • an effective dosage of each active ingredient is administered sequentially, i.e. serially
  • effective dosages of two or more active ingredients are administered together.
  • a synergistic anti-viral effect denotes an antiviral effect which is greater than the predicted purely additive effects of the individual compounds of the combination.
  • the present application provides for methods of inhibiting HCV polymerase in a cell, comprising: contacting a cell infected with HCV with an effective amount of a compound of Formula I-III, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, whereby HCV polymerase is inhibited.
  • the present application provides for methods of inhibiting HCV polymerase in a cell, comprising: contacting a cell infected with IICV with an effective amount of a compound of Formula I-III, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent, whereby HCV polymerase is inhibited.
  • the present application provides for methods of inhibiting HCV polymerase in a cell, comprising: contacting a cell infected with HCV with an effective amount of a compound of Formula I-III, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent selected from the group consisting of one or more interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, mevalonate decarboxylase antagonists, antagonists of the renin-angiotensin system, other anti-fibrotic agents, endothelin antagonists, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV
  • the present application provides for methods of treating HCV in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-III, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides for methods of treating HCV in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-III, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent, whereby HCV polymerase is inhibited.
  • the present application provides for methods of treating HCV in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-III, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent selected from the group consisting of one or more interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, mevalonate decarboxylase antagonists, antagonists of the renin-angiotensin system, other anti-fibrotic agents, endothelin antagonists, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV IRES inhibitors, pharmaco
  • the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for treating an HCV infection in a patient.
  • the invention includes novel and unobvious compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radiolabelled (e.g. 14 C or 3 H) compound of the invention, administering it parenterally in a detectable dose (e.g.
  • metabolite structures are determined in conventional fashion, e.g. by MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well-known to those skilled in the art.
  • the conversion products so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention even if they possess no HCV polymerase inhibitory activity of their own.
  • compositions and methods for determining stability of compounds in surrogate gastrointestinal secretions are known.
  • Compounds are defined herein as stable in the gastrointestinal tract where less than about 50 mole percent of the protected groups are deprotected in surrogate intestinal or gastric juice upon incubation for 1 hour at 37°C. Simply because the compounds are stable to the gastrointestinal tract does not mean that they cannot be hydrolyzed in vivo.
  • the prodrugs of the invention typically will be stable in the digestive system but may be substantially hydrolyzed to the parental drug in the digestive lumen, liver or other metabolic organ, or within cells in general.
  • the mixture is stirred at 0 °C for 0.3 to 2.5 h, and then the reaction is quenched with 1.0 M Et 3 NH 2 CO 3 ( ⁇ 5 mL). The resulting mixture is stirred for additional 0.5-1 h while warming up to room temperature.
  • the mixture is concentrated to dryness, re-dissolved in water (4 mL), and purified by ion exchange HPLC. The fractions containing the desired product is concentrated to dryness, dissolved in water ( ⁇ 5 mL), concentrated to dryness, and again dissolved in water ( ⁇ 5 mL). NaHCO 3 (30-50 mg) is added and concentrated to dryness. The residue is dissolved in water and concentrated to dryness again. This process is repeated 2-5 times.
  • Compound TP-2 was prepared by the general method using Compound 3 as starting material.
  • Non-limiting examples of mono-phosphoramidate prodrugs comprising the instant invention may be prepared according to general Scheme 1.
  • the general procedure comprises the reaction of an amino acid ester salt 19b, e.g., HCl salt, with an aryl dichlorophosphate 19a in the presence of about two to ten equivalents of a suitable base to give the phosphoramidate 19c .
  • suitable bases include, but are not limited to, imidazoles, pyridines such as lutidine and DMAP, tertiary amines such as triethylamine and DABCO, and substituted amidines such as DBN and DBU. Tertiary amines are particularly preferred.
  • the product of each step is used directly in the subsequent steps without recrystallization or chromatography.
  • a nucleoside base 19d reacts with the phosphoramidate 19c in the presence of a suitable base.
  • suitable bases include, but are not limited to, imidazoles, pyridines such as lutidine and DMAP, tertiary amines such as triethylamine and DABCO, and substituted amidines such as DBN and DBU.
  • the product B may be isolated by recrystallization and/or chromatography.
  • Phenyl ethoxyalaninyl phosphorochloridate (124 mg, 0.42 mmol; prepared according to McGuigan et al, J. Med. Chem. 1993, 36, 1048-1052 ) was added to a mixture of Compound 3 (20 mg, 0.065 mmol) and N -methylimidazole (42 uL, 0.52 mmol) in anhydrous trimethyl phosphate (0.8 mL). The reaction mixture is stirred for 3 h at room temperature, and then methanol was added to quench the reaction. The methanol solvent is removed under reduced pressure.
  • reaction was allowed to proceed for an hour before p -nitrophenol (1.9 g, 13.8 mmoL, 1 equiv.) was added to the reaction mixture followed by addition of more TEA (3.8 mL, 13.8 mmoL, 1 equiv.) over five minutes. The reaction was allowed to warm up and proceed for another two hours. The reaction was concentrated in vacuo and taken up in diethyl ether (200 mL). The insoluble salts were filtered off and the filtrate concentrated in vacuo. Flash column chromatography was carried out using 4/1 Hex / EtOAc to furnish a clear oil as C-1a .
  • Raney Ni (about 500 mg) is neutralized by washing with H 2 O, and added to a solution of 1d (about 100 mg) in ethanol (about 10 ml). The mixture is then heated to about 35 to about 80 °C until the reaction is complete. The catalyst is removed by filtration and the solution is concentrated in vacuo. The mixture is concentrated and the residue is purified by IIPLC to give 8 .
  • Compound 1b (about 1 mmol) is placed in a steel bomb reactor.
  • the reactor is charged with liquid ammonia (about 30 mL) and the mixture is stirred at about 0 to 50 °C for about 16 h.
  • the ammonia is evaporated and the residue is purified to give 12a .
  • a solution of 12a (about 100 mg) in ethanol (about 10 ml) is treated with Raney Ni (about 500 mg) that is neutralized by washing with H 2 O.
  • the mixture is then heated to about 35 to about 80 °C until the reaction is complete.
  • the catalyst is removed by filtration and the solution is concentrated in vacuo.
  • the mixture is concentrated and the residue is purified by HPLC to give 12b.
  • Compound 13 is prepared in the same manner as Compound 9 using Compound 12 as a starting material.
  • Compound 14 is prepared by treating Compound 13 with about one to about five equivalents of DCC in pyridine and heating the reaction to reflux for about one to about 24 hours.
  • Compound 14 is isolated by conventional ion exchange and reverse-phase HPLC.
  • Compound 3 (about 0.22 mmmol) is dissolved in anhydrous pyridine (about 2 mL) and chlorotrimethylsilane (about 0.17 mL) is added. The mixture is stirred at about 0 to about 25 °C for about one to about 24 hours. Additional chlorotrimethylsilane (about 0.1 mL) is added and the reaction is stirred for about one to about 24 hours. 4.4'-Dimethoxytrityl chloride (about 0.66 mmol) and DMAP (about 0.11 to about 0.22 mmol) is sequentially added. The mixture is stirred for about one to about 24 hours.
  • a solution of about 2 mmol of Compound 18 in methylene chloride (about 10 mL) is treated with an aqueous solution of trifluoroacetic acid (90%, about 10 mL).
  • the reaction mixture is stirred at about 25 to about 60 °C for about one to about 24 hours.
  • the reaction mixture is diluted with ethanol, the volatiles are evaporated and the residue is purified by chromatography to give Compound 20.
  • Compound 26 is prepared from compound 22 in a matter similar to that for preparation of compound 10.
  • Another aspect of the invention relates to methods of inhibiting viral infections, comprising the step of treating a sample or subject suspected of needing such inhibition with a composition of the invention.
  • samples suspected of containing a virus include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein.
  • biological material samples blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples
  • laboratory samples food, water, or air samples
  • bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein.
  • samples can be contained in any medium including water and organic solvent ⁇ water mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.
  • the anti-virus activity of a compound of the invention after application of the composition can be observed by any method including direct and indirect methods of detecting such activity. Quantitative, qualitative, and semiquantitative methods of determining such activity are all contemplated. Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.
  • the antiviral activity of a compound of the invention can be measured using standard screening protocols that are known.
  • the antiviral activity of a compound can be measured using the following general protocols.
  • BHK21 or A549 cells are trypsinized, counted and diluted to 2x10 5 cells/mL in Hams F-12 media (A549 cells) or RPMI-1640 media (BHK21 cells) supplemented with 2% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
  • 2x10 4 cells are dispensed in a clear 96-well tissue culture plates per well and palced at 37° C, 5% CO 2 overnight. On the next day, the cells are infected with viruses at multiplicity of infection (MOI) of 0.3 in the presence of varied concentrations of test compounds for 1 hour at 37° C and 5% CO 2 for another 48 hours.
  • MOI multiplicity of infection
  • the cells are washed once with PBS and fixed with cold methanol for 10 min. After washing twice with PBS, the fixed cells are blocked with PBS containing 1% FBS and 0.05% Tween-20 for 1 hour at room temperature.
  • the primary antibody solution (4G2) is then added at a concentration of 1:20 to 1:100 in PBS containing 1% FBS and 0.05% Tween-20 for 3 hours.
  • the cells are then washed three times with PBS followed by one hour incubation with horseradish peroxidase(HRP)-conjugated anti-mouse IgG (Sigma, 1:2000 dilution).
  • TMB 3,3',5,5'-tetramethylbenzidine
  • Sigma a substrate solution
  • the reaction is stopped by addition of 0.5 M sulfuric acid.
  • the plates are read at 450 nm abosorbance for viral load quantification.
  • the cells are washed three times with PBS followed by incubation with propidium iodide for 5 min.
  • the plate is read in a Tecan SafireTM reader (excitation 537 nm, emission 617 nm) for cell number quantification. Dose response curves are plotted from the mean absorbance versus the log of the concentration of test compounds.
  • the EC 50 is calculated by non-linear regression analysis. A positive control such as N-nonyl-deoxynojirimycin may be used.
  • BHK21 cells are trypsinized and diluted to a concentration of 4 x 10 5 cells/mL in RPMI-1640 media supplemented with 2% FBS and 1% penicillin/streptomycin.
  • Huh7 cells are trypsinized and diluted to a concentration of 4 x 10 5 cells/mL in DMEM media supplemented with 5% FBS and 1% penicillin/streptomycin.
  • a 50 microliter of cell suspension (2 x 10 4 cells) is dispensed per well in a 96-well optical bottom PIT polymer-based plates (Nunc).
  • the plates containing the virus and the compounds are further incubated at 37°C, 5% CO 2 for 72 hours.
  • 100 microliters of CellTiter-GloTM reagent is added into each well. Contents are mixed for 2 minutes on an orbital shaker to induce cell lysis.
  • the plates are incubated at room temperature for 10 minutes to stabilize luminescent signal. Lumnescence reading is recorded using a plate reader.
  • a positive control such as N-nonyl-deoxynojirimycin may be used.
  • mice Six to ten week old AG129 mice (B&K Universal Ltd, Hll, UK) are housed in individually ventilated cages. Mice are injected intraperitoneally with 0.4 mL TSV01 dengue virus 2 suspension. Blood samples are taken by retro orbital puncture under isoflurane anaesthesia. Blood samples are collected in tubes containing sodium citrate to a final concentration of 0.4%, and immediately centrifuged for 3 minutes at 6000g to obtain plasma. Plasma (20 microliters) is diluted in 780 microliters RPMI-1640 medium and snap frozen in liquid nitrogen for plaque assay analysis. The remaining plasma is reserved for cytokine and NS1 protein level determination. Mice develop dengue viremia rising over several days, peaking on day 3 post-infection.
  • a compound of the invention is dissolved in vehicle fluid, e.g. 10% ethanol, 30% PEG 300 and 60% D5W (5% dextrose in water; or 6N HCl (1.5 eq):1N NaOH (pH adjusted to 3.5): 100 mM citrate buffer pH 3.5 (0.9% v/v:2.5% v/v: 96.6% v/v).
  • vehicle fluid e.g. 10% ethanol, 30% PEG 300 and 60% D5W (5% dextrose in water; or 6N HCl (1.5 eq):1N NaOH (pH adjusted to 3.5): 100 mM citrate buffer pH 3.5 (0.9% v/v:2.5% v/v: 96.6% v/v).
  • Group 1 is dosed by oral gavage of 200 mL/mouse with 0.2 mg/kg of a compound of the invention twice a day (once early in the morning and once late in the afternoon) for three consecutive days starting on day 0 (first dose just before dengue infection).
  • Groups 2, 3 and 4 are dosed the same way with 1 mg/kg, 5 mg/kg and 25 mg/kg of the compound, respectively.
  • a positive control may be used, such as (2R,3R,4R,5R)-2-(2-amino-6-hydroxy-purin-9-yl)-5-hydroxymethyl-3-methyl-tetrahydro-furan-3,4-diol, dosed by oral gavage of 200 microliters/mouse the same way as the previous groups.
  • a further group is treated with only vehicle fluid.
  • NS5b polymerase assay (40 ⁇ L) was assembled by adding 28 ⁇ L polymerase mixture (final concentration: 50 mM Tris-HCl at pH 7.5, 10 mM KCL, 5 mM MgCl 2 , 1 mM DTT, 10 mM EDTA, 4 ng/ ⁇ L of RNA template, and 75 nM HCV ⁇ 21 NS5b polymerase) to assay plates followed by 4 ⁇ L of compound dilution.
  • polymerase mixture final concentration: 50 mM Tris-HCl at pH 7.5, 10 mM KCL, 5 mM MgCl 2 , 1 mM DTT, 10 mM EDTA, 4 ng/ ⁇ L of RNA template, and 75 nM HCV ⁇ 21 NS5b polymerase
  • the polymerase and compound were pre-incubated at 35 °C for 10 minute before the addition of 8 ⁇ L of nucleotide substrate mixture (33P- ⁇ -labeled competing nucleotide at K M and 0.5 mM of the remaining three nucleotides).
  • the assay plates were covered and incubated at 35 °C for 90 min. Reactions were then filtered through 96-well DEAE-81 filter plates via vacuum. The filter plates were then washed under vacuum with multiple volumes of 0.125 M NaHPO 4 , water, and ethanol to remove unincorporated label. Plates were then counted on TopCount to assess the level of product synthesis over background controls.
  • the IC50 value is determined using Prism fitting program.
  • compounds described herein inhibited NS5b polymerase with an IC 50 's below 1000 ⁇ M, more preferably below 100 ⁇ M, and most preferably below 10 ⁇ M.
  • compound TP-1 has an IC 50 of 0.15 ⁇ M against both wild type HCV polymerase and the S282T mutant enzyme.
  • Table II below shows the activity of TP-1 and TP-2 against both wild type and the S282T mutant enzyme compared to the activities obtained with the triphosphate of 2'-methyl guanidine and the triphosphate of (2R,3R,4R,5R)-2-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxyxymethyl)-3-methyl-tetrahydrofuran-2-carbonitrile.
  • This demonstrates that replacing the 2' OH of the pyrrolo[1,2-f][1,2,4]triazin-7-yl nucleosides with a 2' F unexpectedly confers activity against resistant S282T HCV mutant strains of virus.
  • Replicon cells were seeded in 96-well plates at a density of 8 x 10 3 cells per well in 100 ⁇ L of culture medium, excluding Geneticin. Compound was serially diluted in 100% DMSO and then added to the cells at a 1:200 dilution, achieving a final concentration of 0.5% DMSO and a total volume of 200 ⁇ L. Plates were incubated at 37°C for 3 days, after which culture medium was removed and cells were lysed in lysis buffer provided by Promega's luciferase assay system. Following the manufacturer's instruction, 100 ⁇ L of luciferase substrate was added to the lysed cells and luciferase activity was measured in a TopCount luminometer.
  • compounds described herein have EC50's below 1000 ⁇ M, more preferably below 100 ⁇ M, and most preferably below 10 ⁇ M.
  • the activities of representative compounds of Formula I are shown in the Table below.
  • cytotoxicity of a compound of the invention can be determined using the following general protocol.
  • the assay is based on the evaluation of cytotoxic effect of tested compounds using a metabolic substrate.
EP16196457.2A 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment Active EP3150608B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24429709P 2009-09-21 2009-09-21
PCT/US2010/049471 WO2011035231A1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
EP10763083.2A EP2480552B1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP10763083.2A Division EP2480552B1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (2)

Publication Number Publication Date
EP3150608A1 EP3150608A1 (en) 2017-04-05
EP3150608B1 true EP3150608B1 (en) 2019-04-10

Family

ID=43031517

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10763083.2A Active EP2480552B1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
EP16196457.2A Active EP3150608B1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10763083.2A Active EP2480552B1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Country Status (32)

Country Link
EP (2) EP2480552B1 (sr)
JP (3) JP5795766B2 (sr)
KR (2) KR20180006499A (sr)
CN (1) CN102596958A (sr)
AP (1) AP2012006189A0 (sr)
AU (4) AU2010295373B2 (sr)
BR (3) BR122021012877B8 (sr)
CA (1) CA2773772C (sr)
CL (1) CL2012000707A1 (sr)
CR (2) CR20190103A (sr)
CY (1) CY1118605T1 (sr)
DK (1) DK2480552T3 (sr)
EA (1) EA201200525A1 (sr)
EC (1) ECSP12011817A (sr)
ES (2) ES2730805T3 (sr)
HR (1) HRP20170197T1 (sr)
HU (1) HUE032252T2 (sr)
IL (2) IL218599A (sr)
LT (1) LT2480552T (sr)
ME (1) ME02656B (sr)
MX (1) MX352646B (sr)
NZ (1) NZ599402A (sr)
PE (3) PE20120995A1 (sr)
PL (1) PL2480552T3 (sr)
PT (1) PT2480552T (sr)
RS (1) RS55699B1 (sr)
SG (1) SG179194A1 (sr)
SI (1) SI2480552T1 (sr)
SM (1) SMT201700091B (sr)
UA (1) UA110466C2 (sr)
WO (1) WO2011035231A1 (sr)
ZA (1) ZA201202175B (sr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
NZ599402A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) * 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CN102858790A (zh) * 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
CR20170278A (es) 2010-07-22 2017-09-29 Gilead Sciences Inc Métodos y compuestos para tratar infecciones virales por paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR101879887B1 (ko) * 2010-09-20 2018-07-18 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체
BR112013012245B1 (pt) 2010-11-19 2022-09-27 Janssen Sciences Ireland Uc Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv
CA2822037A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP3351552B1 (en) * 2012-03-13 2021-05-19 Gilead Sciences, Inc. 2'-substituted carba-nucleoside analogs for antiviral treatment
WO2014059901A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014059902A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US9732111B2 (en) 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2852867C (en) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015095419A1 (en) * 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016160646A1 (en) 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
CN104945437B (zh) * 2015-05-19 2017-03-01 广州诺威生物技术有限公司 一种嘧啶类新化合物
SG10202001878WA (en) 2015-09-16 2020-04-29 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
TWI740910B (zh) * 2016-03-09 2021-10-01 美商艾洛斯生物製藥公司 非環抗病毒劑
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
TW201811339A (zh) * 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
KR20210125025A (ko) * 2019-02-07 2021-10-15 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
US20210292348A1 (en) 2020-02-18 2021-09-23 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
CR20220675A (es) 2020-06-24 2023-02-15 Gilead Sciences Inc Análogos de nucleósido de 1´- ciano y usos de los mismos
KR20230057411A (ko) 2020-08-27 2023-04-28 길리애드 사이언시즈, 인코포레이티드 바이러스 감염 치료를 위한 화합물 및 방법
EP4323064A1 (en) * 2021-04-14 2024-02-21 Yeda Research and Development Co. Ltd Anti-viral and anti-tumoral compounds, and uses thereof
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
EP4337323A1 (en) * 2021-05-14 2024-03-20 BM Pharma Consulting Pty. Ltd Bicyclic heterocyclic compounds for prophylaxis and treatment of viral infections
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
MX2009007333A (es) * 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
DK2480559T3 (da) * 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
NZ599402A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2011035231A1 (en) 2011-03-24
PT2480552T (pt) 2017-02-14
BR112012006261A2 (pt) 2020-08-18
AU2016262676A1 (en) 2016-12-08
ECSP12011817A (es) 2013-02-28
BR112012006261B1 (pt) 2021-12-21
LT2480552T (lt) 2017-02-10
CR20190103A (es) 2019-09-19
AU2016262676B2 (en) 2018-03-29
BR122021021135B1 (pt) 2022-08-30
CA2773772C (en) 2018-06-26
HRP20170197T1 (hr) 2017-04-07
JP2015187126A (ja) 2015-10-29
CR20120186A (es) 2012-07-04
AU2018204449A1 (en) 2018-07-12
JP2017075146A (ja) 2017-04-20
PL2480552T3 (pl) 2017-06-30
EA201200525A1 (ru) 2012-09-28
SMT201700091B (it) 2017-03-08
CY1118605T1 (el) 2017-07-12
IL248110A0 (en) 2016-11-30
AU2018204449B2 (en) 2020-01-23
SG179194A1 (en) 2012-05-30
JP2013505265A (ja) 2013-02-14
NZ599402A (en) 2014-02-28
IL218599A (en) 2016-12-29
PE20160217A1 (es) 2016-05-18
MX2012003391A (es) 2012-06-27
AP2012006189A0 (en) 2012-04-30
CL2012000707A1 (es) 2012-08-31
KR101818779B1 (ko) 2018-01-15
AU2010295373B2 (en) 2016-09-29
AU2020202600B2 (en) 2021-07-01
SI2480552T1 (sl) 2017-02-28
BR122021012877B1 (pt) 2021-10-19
CN102596958A (zh) 2012-07-18
EP3150608A1 (en) 2017-04-05
KR20120102605A (ko) 2012-09-18
EP2480552B1 (en) 2016-11-09
AU2020202600A1 (en) 2020-05-14
DK2480552T3 (en) 2017-02-20
CA2773772A1 (en) 2011-03-24
RS55699B1 (sr) 2017-07-31
JP5795766B2 (ja) 2015-10-14
AU2010295373A1 (en) 2012-04-26
IL218599A0 (en) 2012-05-31
EP2480552A1 (en) 2012-08-01
ES2730805T3 (es) 2019-11-12
BR122021012877B8 (pt) 2021-12-14
PE20210668A1 (es) 2021-04-05
KR20180006499A (ko) 2018-01-17
ZA201202175B (en) 2012-11-28
MX352646B (es) 2017-12-04
ES2614651T3 (es) 2017-06-01
ME02656B (me) 2017-06-20
HUE032252T2 (en) 2017-09-28
UA110466C2 (ru) 2016-01-12
JP6033362B2 (ja) 2016-11-30
PE20120995A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
AU2020202600B2 (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
AU2011306066B2 (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
OA16229A (en) 2'-Fluoro substituted carba-nucleoside analogs for antiviral treatment.
OA16347A (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment.
EA046452B1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
OA16370A (en) Mass transfert column.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161028

AC Divisional application: reference to earlier application

Ref document number: 2480552

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236200

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20181004

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTC Intention to grant announced (deleted)
AC Divisional application: reference to earlier application

Ref document number: 2480552

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

INTG Intention to grant announced

Effective date: 20190301

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1118484

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010058242

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190410

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1118484

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190910

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190710

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2730805

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190710

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190711

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010058242

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

26N No opposition filed

Effective date: 20200113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190920

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230810

Year of fee payment: 14

Ref country code: IE

Payment date: 20230710

Year of fee payment: 14

Ref country code: GB

Payment date: 20230727

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230808

Year of fee payment: 14

Ref country code: DE

Payment date: 20230726

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231005

Year of fee payment: 14